Synmosa Biopharma Bilan de santé

Santé financière contrôle des critères 6/6

Synmosa Biopharma possède un total de capitaux propres de NT$8.3B et une dette totale de NT$2.5B, ce qui porte son ratio d'endettement à 30.3%. Son actif total et son passif total sont NT$12.2B et de NT$3.9B. L'EBIT de Synmosa Biopharma est NT$716.9M ce qui fait que son ratio de couverture des intérêts 18.8. Elle dispose de liquidités et de placements à court terme de NT$1.8B.

Informations clés

30.3%

Ratio d'endettement

NT$2.53b

Dette

Ratio de couverture des intérêts	18.8x
Argent liquide	NT$1.78b
Fonds propres	NT$8.33b
Total du passif	NT$3.85b
Total des actifs	NT$12.18b

Mises à jour récentes de la santé financière

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4114 ( NT$4.9B ) dépassent ses passifs à court terme ( NT$2.1B ).

Passif à long terme: Les actifs à court terme de 4114 ( NT$4.9B ) dépassent ses passifs à long terme ( NT$1.8B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 4114 ( 9% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 4114 a été réduit de 78% à 30.3% au cours des 5 dernières années.

Couverture de la dette: La dette de 4114 est bien couverte par le flux de trésorerie opérationnel ( 29.2% ).

Couverture des intérêts: Les paiements d'intérêts de 4114 sur sa dette sont bien couverts par l'EBIT ( 18.8 x couverture).

Synmosa Biopharma Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.39 (vs NT$0.32 in 3Q 2023)

Synmosa Biopharma Corporation has filed a Follow-on Equity Offering.

Synmosa Biopharma Corporation to Report Q3, 2024 Results on Nov 13, 2024

Second quarter 2024 earnings released: EPS: NT$0.53 (vs NT$0.42 in 2Q 2023)

Synmosa Biopharma Corporation to Report Q2, 2024 Results on Aug 13, 2024

Dividend of NT$0.60 announced

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 13, 2024

First quarter 2024 earnings released: EPS: NT$0.48 (vs NT$0.35 in 1Q 2023)

Synmosa Biopharma Corporation to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$1.61 (vs NT$2.25 in FY 2022)

Synmosa Biopharma Corporation, Annual General Meeting, May 30, 2024

Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee

Third quarter 2023 earnings released: EPS: NT$0.35 (vs NT$0.32 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: NT$0.46 (vs NT$1.13 in 2Q 2022)

Upcoming dividend of NT$0.56 per share at 1.4% yield

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 15, 2023

Synmosa Biopharma Corporation Appoints Tu, San-Chien as Additional Independent Director

New minor risk - Shareholder dilution

Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.24 (vs NT$0.23 in 2Q 2021)

Upcoming dividend of NT$0.51 per share

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Announces Changes to the Compensation Committee

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.20 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$2.20 in FY 2020)

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2022

Third quarter 2021 earnings released: EPS NT$0.24 (vs NT$0.25 in 3Q 2020)

Upcoming dividend of NT$0.30 per share

Second quarter 2021 earnings released: EPS NT$0.29 (vs NT$1.66 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.23 (vs NT$0.26 in 1Q 2020)

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Synmosa Biopharma Corporation Approves Cash Dividends

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2021

Full year 2020 earnings released: EPS NT$2.46 (vs NT$0.20 in FY 2019)

Revenue beats expectations

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$24.05

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day high - NT$27.60

Price target raised to NT$28.00

New 90-day high - NT$26.95

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines